Prometheus and Longboard make the leap to Nasdaq with 9-figure offerings and are joined by a Falcon Edge-backed SPAC
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
It’s been hard to match the whirlwind first two months of the year in terms of IPO momentum, and March so far has been relatively quiet on that front. But that doesn’t mean companies aren’t taking the leap — now, two more biotechs and a SPAC are hopping aboard the train.
Frontier Acquisition, a SPAC led by Falcon Edge Capital’s Rick Gerson, took home the largest raise at $200 million, followed closely by Prometheus Biosciences with $190 million. And Longboard Pharmaceuticals secured an $80 million jump onto Nasdaq, just over four months after launching out of Arena Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.